Boitz K, Angermeyer M C, Löffler W, Müller P, Priebe S
Klinik und Poliklinik für Psychiatrie, Universität Leipzig.
Psychiatr Prax. 1999 Jul;26(4):188-93.
Subjective evaluations by schizophrenic patients of clozapine treatment were assessed as part of an exploratory study.
A problem-centred interview was carried out with 80 patients at discharge from in-patient or day hospital treatment.
In addition to expected effects (improvement or stabilisation of one's state of mental health, antipsychotic effects), patients surprisingly often highlighted clozapine's calming and relaxing effect as well as improved sleep as particularly positive. While more than half of the respondents expected a worsening of their condition in case they stopped taking their medication, only every fifth patient feared a relapse. Among the negative effects, fatigue and sedation were cited by far the most often. The absence of extrapyramidal side effects was clearly noted as an advantage of clozapine. Only every tenth of those questioned was aware of the risks for the haemotopoietic system associated with the drug. With regard to the obligatory blood tests, a surprisingly large number of patients was indifferent or stated that they had no opinion on the matter.
Possible implications for patient information and compliance will be discussed.
作为一项探索性研究的一部分，对精神分裂症患者使用氯氮平治疗的主观评价进行评估。
对80名从住院或日间医院治疗出院的患者进行了以问题为中心的访谈。
除了预期效果（改善或稳定心理健康状态、抗精神病作用）外，患者令人惊讶地经常强调氯氮平的镇静和放松作用以及睡眠改善是特别积极的方面。虽然超过一半的受访者预计停药后病情会恶化，但只有五分之一的患者担心复发。在不良反应中，疲劳和镇静是被提及最多的。氯氮平没有锥体外系副作用显然被视为一项优势。只有十分之一的受访者意识到该药物与造血系统相关的风险。关于强制性血液检查，数量惊人的患者对此漠不关心或表示对此事没有看法。
将讨论对患者信息告知和依从性的可能影响。
